Wockhardt announced healthy results for the first quarter of FY12. The pharma firm's revenues shot up 14% and the operating margins soared as well.
In an interview to CNBC-TV18, Habil Khorakiwala, chariman of the Wockhardt Group said the EBITDA growth for FY12 is likely to be at 72%, while the margins are seen at 30%.Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
